Hyperbilirubinemia in preterm infants in Japan: New treatment criteria

Area of Science:

• Neonatology
• Pediatric Neurology
• Medical Imaging

Background:

• Kobe University established neonatal hyperbilirubinemia treatment criteria in 1992.
• Chronic bilirubin encephalopathy is now diagnosed in preterm infants using MRI and auditory brainstem response.
• Previous criteria did not adequately address the evolving understanding of bilirubin encephalopathy in preterm infants.

Purpose of the Study:

• To revise the Kobe University treatment criteria for hyperbilirubinemia in preterm infants.
• To incorporate updated diagnostic methods and clinical findings for chronic bilirubin encephalopathy.
• To establish new guidelines for managing neonatal hyperbilirubinemia in preterm infants.

Main Methods:

• Classification of newborns by gestational age at birth or corrected gestational age, replacing birthweight.
• Introduction of three treatment tiers: standard phototherapy, intensive phototherapy, and albumin therapy/exchange transfusion.
• Decision-making for treatment initiation based on total serum bilirubin and serum unbound bilirubin levels, adjusted for age ( <7 days vs. ≥7 days corrected age).

Main Results:

• Revised criteria prioritize gestational age over birthweight for classification.
• A tiered treatment approach (standard phototherapy, intensive phototherapy, albumin therapy/exchange transfusion) was established.
• Treatment initiation thresholds are now age-dependent, considering both birth and corrected gestational age.

Conclusions:

• The 2017 revised Kobe University criteria offer a new framework for managing hyperbilirubinemia in preterm infants.
• The revised guidelines aim to better address the risk of chronic bilirubin encephalopathy.
• Further research is required to validate the efficacy of the 2017 criteria in preventing chronic bilirubin encephalopathy.